← Back to headlines
Soligenix Advances CTCL Research with Interim Analysis
Soligenix (NASDAQ: SNGX) has announced progress in its Cutaneous T-Cell Lymphoma (CTCL) research, presenting results from an interim analysis and comparative study.
18 Apr, 17:59 — 18 Apr, 17:59
Related Stories
IT Outage Disrupts Medical Records in Denmark's Central Jutland Region
8m ago
KGL Foundation Provides Free Health Screening and Blood Donation in Ghana's Oti Region
11m ago
HiPP Baby Food Recalled in Austria After Rat Poison Found
13m ago
Doctor's Death Exposes Gaps in Nigeria's Maternal Healthcare
17m ago